Brokerages Expect Zoetis (ZTS) Will Announce Earnings of $0.70 Per Share

Analysts predict that Zoetis (NYSE:ZTS) will post $0.70 earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Zoetis’ earnings, with the lowest EPS estimate coming in at $0.68 and the highest estimate coming in at $0.73. Zoetis posted earnings per share of $0.53 during the same quarter last year, which indicates a positive year-over-year growth rate of 32.1%. The firm is expected to announce its next earnings results before the market opens on Wednesday, May 2nd.

According to Zacks, analysts expect that Zoetis will report full year earnings of $3.04 per share for the current financial year, with EPS estimates ranging from $2.96 to $3.10. For the next fiscal year, analysts expect that the firm will report earnings of $3.43 per share, with EPS estimates ranging from $3.35 to $3.56. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Zoetis.

How to Become a New Pot Stock Millionaire

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the business earned $0.47 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year.

ZTS has been the topic of several research analyst reports. Jefferies Group restated a “buy” rating and set a $96.00 price target on shares of Zoetis in a research report on Friday. Credit Suisse Group boosted their price target on shares of Zoetis from $83.00 to $89.00 and gave the stock an “outperform” rating in a research report on Thursday, April 5th. ValuEngine upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BMO Capital Markets restated a “hold” rating on shares of Zoetis in a research report on Monday, January 8th. Finally, Piper Jaffray restated a “buy” rating and set a $86.00 price target on shares of Zoetis in a research report on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $80.89.

In related news, insider Roman Trawicki sold 23,885 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $82.00, for a total transaction of $1,958,570.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 35,663 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the sale, the executive vice president now directly owns 49,919 shares in the company, valued at $4,044,437.38. The disclosure for this sale can be found here. Insiders sold a total of 112,952 shares of company stock worth $9,219,843 over the last three months. Insiders own 0.35% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Robecosam AG grew its stake in Zoetis by 4.6% in the 4th quarter. Robecosam AG now owns 15,346 shares of the company’s stock valued at $1,111,000 after acquiring an additional 679 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in Zoetis by 4.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 16,828 shares of the company’s stock valued at $1,212,000 after acquiring an additional 697 shares during the last quarter. Sandy Spring Bank grew its stake in Zoetis by 2.3% in the 4th quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock valued at $2,235,000 after acquiring an additional 708 shares during the last quarter. Penserra Capital Management LLC boosted its stake in shares of Zoetis by 18.6% during the 4th quarter. Penserra Capital Management LLC now owns 4,550 shares of the company’s stock worth $327,000 after purchasing an additional 715 shares during the last quarter. Finally, Advisory Services Network LLC boosted its stake in shares of Zoetis by 42.4% during the 4th quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock worth $175,000 after purchasing an additional 721 shares during the last quarter. 92.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE ZTS traded down $0.39 during trading on Tuesday, hitting $83.57. The company had a trading volume of 1,162,616 shares, compared to its average volume of 2,575,120. Zoetis has a fifty-two week low of $53.00 and a fifty-two week high of $85.73. The firm has a market cap of $40,741.90, a price-to-earnings ratio of 34.82, a price-to-earnings-growth ratio of 1.88 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be paid a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is 20.83%.

ILLEGAL ACTIVITY NOTICE: This report was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://weekherald.com/2018/04/22/brokerages-expect-zoetis-zts-will-announce-earnings-of-0-70-per-share.html.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply